MiniMed Group Inc (NASDAQ:MMED) Receives Consensus Recommendation of “Moderate Buy” from Analysts

MiniMed Group Inc (NASDAQ:MMED) has earned an average recommendation of “Moderate Buy” from the fifteen ratings firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and twelve have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $21.3333.

A number of equities research analysts recently commented on MMED shares. BTIG Research started coverage on shares of MiniMed Group in a report on Tuesday, March 31st. They issued a “buy” rating and a $25.00 price target on the stock. William Blair assumed coverage on MiniMed Group in a research report on Tuesday, March 31st. They issued an “outperform” rating for the company. Barclays began coverage on MiniMed Group in a research note on Wednesday, April 1st. They issued an “overweight” rating and a $26.00 target price on the stock. Weiss Ratings downgraded MiniMed Group from a “sell (d)” rating to a “sell (e+)” rating in a research note on Tuesday, June 30th. Finally, Benchmark reissued a “buy” rating on shares of MiniMed Group in a report on Thursday, June 4th.

MiniMed Group Price Performance

NASDAQ MMED opened at $15.02 on Thursday. The stock has a market capitalization of $4.22 billion and a P/E ratio of -22.09. MiniMed Group has a 52-week low of $10.65 and a 52-week high of $20.48. The stock’s 50-day moving average is $13.25.

MiniMed Group (NASDAQ:MMED) last released its earnings results on Wednesday, June 3rd. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.46). The business had revenue of $837.00 million for the quarter. MiniMed Group’s revenue was up 15.6% on a year-over-year basis.

MiniMed Group Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.